Salmeterol, a Long-Acting β2-Adrenergic Receptor Agonist, Inhibits Macrophage Activation by Lipopolysaccharide From Porphyromonas gingivalis.

Abstract

BACKGROUND:

Salmeterol is a long-acting β2-adrenergic receptor agonist used to treat chronic obstructive pulmonary disease. The authors of the current study previously showed that preincubation of primary microglial-enriched cells with salmeterol could inhibit the inflammatory response induced by Escherichia coli lipopolysaccharide (LPS), a Toll-like receptor (TLR)-4 agonist. In this study, the authors sought to determine if salmeterol had a similar inhibitory effect on the inflammatory response of the murine macrophage cell line RAW264.7 and human monocyte THP-1 to LPS from Porphyromonas gingivalis (PgLPS), an oral microbe implicated in the pathogenesis of periodontal disease.

METHODS:

RAW264.7 and THP-1 cells were pretreated with salmeterol, followed by PgLPS, and monitored for production of inflammatory mediators by enzyme-linked immunosorbent assay. The nitric oxide concentration and nuclear factor-kappa B (NF-κB) activity were measured by Griess method and secretory alkaline phosphatase reporter activity assay, respectively. Reverse-transcriptase polymerase chain reaction and immunoblot analysis were used to measure messenger RNA and protein levels. Nuclear translocation of NF-κB was detected by immunofluorescence.

RESULTS:

Pretreatment with salmeterol significantly inhibited production of proinflammatory mediators by RAW264.7 and THP-1 cells. Salmeterol downregulated PgLPS-mediated phosphorylation of the extracellular signal-regulated kinase 1/2 and c-Jun N-terminal kinase but not p38 mitogen-activated protein kinases (MAPKs). Salmeterol also attenuated activation of NF-κB via inhibition of nuclear translocation of p65-NFκB, the transcriptional activity of NF-κB and IκBα phosphorylation.

CONCLUSION:

Salmeterol can significantly inhibit activation of macrophage-mediated inflammation by PgLPS, suggesting that use of salmeterol may be an effective treatment in inhibiting or lessening the inflammatory response mediated through TLR pathway activation.

• Authors: Monika Sharma, Lindsay Patterson, Elisha Chapman, Patrick M Flood
• Journal: Journal of periodontology (J Periodontol) Vol. 88 Issue 7 Pg. 681-692 (07 2017) ISSN: 1943-3670 [Electronic] United States
• PMID: 28398147 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Adrenergic beta-2 Receptor Agonists
• Lipopolysaccharides
• NF-kappa B
• NF-KappaB Inhibitor alpha
• Salmeterol Xinafoate
• p38 Mitogen-Activated Protein Kinases

Topics

• Adrenergic beta-2 Receptor Agonists (pharmacology, therapeutic use)
• Animals
• Down-Regulation
• Enzyme-Linked Immunosorbent Assay
• Humans
• Inflammation (drug therapy)
• Lipopolysaccharides (pharmacology)
• Macrophage Activation (drug effects)
• Mice
• NF-KappaB Inhibitor alpha (metabolism)
• NF-kappa B (metabolism)
• Phosphorylation
• Porphyromonas gingivalis
• RAW 264.7 Cells
• Salmeterol Xinafoate (pharmacology, therapeutic use)
• THP-1 Cells
• p38 Mitogen-Activated Protein Kinases (metabolism)